Yurii Feshchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yurii Feshchenko has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Svitlana Opimakh
SI “National scientific center of phthisiatry, pulmonology and allergology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine
5 shared publications - M. O. Polianska
SI “National scientific center of phthisiatry, pulmonology and allergology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine
4 shared publications - Galyna Gumeniuk
SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE
3 shared publications V.I. Ignatieva
3 shared publications- Iryna V. Liskina
SI “National scientific center of phthisiatry, pulmonology and allergology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine
2 shared publications - L.M. Protsyk
SI “National scientific center of phthisiology, pulmonology and allergology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 3,p. 5-13
Features of Psychological Disorders in Patients with Severe Asthma Exacerbations in the Wartime Conditions
The potential harm to lung health due to war is difficult to overestimate. An important factor influencing the course of bronchial asthma is stress and psychological trauma, as well as an increased risk of anxiety and depression, and a high probability of panic attacks, which exacerbate respiratory symptoms and worsen the response to standard therapy. Objective — to investigate the features of psychological disorders in patients with severe asthma exacerbations in the wartime conditions. Materials and methods. One hundred patients with severe asthma exacerbations were examined, including 40 military personnel and 60 civilians. All 100 patients were surveyed using the following questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), mMRC Dyspnoea Scale (Modified British Medical Research Council), PHQ-9 (Patient Health Questionnaire — Depression), Beck Anxiety Inventory, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and Athens Insomnia Scale (AIS). Results and discussion. The results of the questionnaire analysis showed that all studied patients had uncontrolled asthma and most of them had clinical signs of depression. All patients had anxiety disorders and, on average, a moderate level of sleepiness, as well as poor sleep quality and subthreshold or moderate insomnia. In comparison with civilians, military personnel with severe asthma exacerbations had significantly worse asthma control, a higher degree of dyspnoea, a higher percentage of patients with clinically significant sleepiness, and severe insomnia. Among military personnel, there was worse sleep quality — (11.9 ± 0.7) points according to the PSQI, (14.8 ± 1.0) points of the ISI, and (13.9 ± 0.9) points of the AIS compared to civilians — (9.9 ± 0.6), (12.3 ± 0.7), and (11.0 ± 0.7) points, respectively (p < 0.05). Among civilians, the proportion of patients with clinical signs of depression, clinically meaningful anxiety and severe anxiety is significantly higher. Conclusions. The features of psychological disorders in patients with severe asthma exacerbations in the wartime conditions are clinically significant depression, severe anxiety, sleep quality disorders, insomnia, and daytime sleepiness in most patients. Clinicians should consider the potential risk of depression, anxiety, sleep problems in asthma patients, and offer appropriate counselling and interventions to patients.
- 24 September 2026
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 3,p. 5-13
Open AccessFeatures of Psychological Disorders in Patients with Severe Asthma Exacerbations in the Wartime Conditions
The potential harm to lung health due to war is difficult to overestimate. An important factor influencing the course of bronchial asthma is stress and psychological trauma, as well as an increased risk of anxiety and depression, and a high probability of panic attacks, which exacerbate respiratory symptoms and worsen the response to standard therapy. Objective — to investigate the features of psychological disorders in patients with severe asthma exacerbations in the wartime conditions. Materials and methods. One hundred patients with severe asthma exacerbations were examined, including 40 military personnel and 60 civilians. All 100 patients were surveyed using the following questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), mMRC Dyspnoea Scale (Modified British Medical Research Council), PHQ-9 (Patient Health Questionnaire — Depression), Beck Anxiety Inventory, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), and Athens Insomnia Scale (AIS). Results and discussion. The results of the questionnaire analysis showed that all studied patients had uncontrolled asthma and most of them had clinical signs of depression. All patients had anxiety disorders and, on average, a moderate level of sleepiness, as well as poor sleep quality and subthreshold or moderate insomnia. In comparison with civilians, military personnel with severe asthma exacerbations had significantly worse asthma control, a higher degree of dyspnoea, a higher percentage of patients with clinically significant sleepiness, and severe insomnia. Among military personnel, there was worse sleep quality — (11.9 ± 0.7) points according to the PSQI, (14.8 ± 1.0) points of the ISI, and (13.9 ± 0.9) points of the AIS compared to civilians — (9.9 ± 0.6), (12.3 ± 0.7), and (11.0 ± 0.7) points, respectively (p < 0.05). Among civilians, the proportion of patients with clinical signs of depression, clinically meaningful anxiety and severe anxiety is significantly higher. Conclusions. The features of psychological disorders in patients with severe asthma exacerbations in the wartime conditions are clinically significant depression, severe anxiety, sleep quality disorders, insomnia, and daytime sleepiness in most patients. Clinicians should consider the potential risk of depression, anxiety, sleep problems in asthma patients, and offer appropriate counselling and interventions to patients.
- Open Access
- 31 March 2026
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 31 (1) , 12-22
Young chronic obstructive lung disease or constrictive bronchiolitis: difficulties in differential diagnosis in the context of hostilities
Confirmation of the diagnosis of chronic obstructive pulmonary disease (COPD) in young patients is a difficult but important challenge for respiratory physicians, as it is the key to prescribing the correct therapy and has an important medical and social role. The term “young COPD” is used in the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2026 GOLD Report to refer to patients with COPD aged 20-50 years. The aim of the study was to describe the features of the diagnosis of young COPD and to systematize the latest data on the differential diagnosis with obliterative bronchiolitis. We conducted a literature search on the relevant topics and keywords in the scientific databases PubMed, Google Scholar, Scopus and Web of Science. After a detailed analysis, 53 literature sources were selected and evaluated, 90% of which were published over the past 5 years and contained the most up-to-date information. It has been established that genetic factors prevail over the influence of environmental factors in the development of COPD in young patients, among which the most common cause is congenital alpha-1 antitrypsin deficiency. However, there is a growing trend of airway damage as a result of smoking modern devices for nicotine and tobacco use, such as new generations of e-cigarettes and tobacco heating devices, which are especially popular among youth. The diagnosis of COPD in people younger than 50 years can be considered if the patient has not only persistent post-bronchodilator obstruction, but also presents a long history of smoking (≥10 pack-years) and typical changes on computed tomography of the lungs (emphysema and abnormalities of small or large bronchi). In the context of active hostilities, an important competitive diagnosis in such patients is obliterative bronchiolitis. This disease is manifested by external compression and sometimes obliteration of bronchioles, and should be considered when five factors are combined, including an atypical young age for COPD, typical symptoms, persistent bronchial obstruction on spirometry, the formation of the “air trapping” symptom on computed tomography of the lungs, no signs of emphysema, and an anamnesis of inhalation of toxic substances. Thus, confirmation of the diagnosis of COPD in people under 50 years of age requires a comprehensive assessment of the patient's condition, which should include pulmonary function testing (spirometry), imaging studies (computed tomography of the lungs), and genetic testing (alpha-1 antitrypsin deficiency). Given that in the context of active hostilities related to the War for Independence of Ukraine, both military personnel and civilians may be exposed to significant negative effects of toxic and irritating substances on the respiratory system, obliterative bronchiolitis should be considered as a mandatory component of the differential diagnosis in young patients. To verify the diagnosis of obliterative bronchiolitis, computed tomography of the lungs and confirmation of inhalation of toxic substances are crucial. However, in certain clinical situations, only lung biopsy assessment can distinguish between these two diagnoses.
- 31 March 2026
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 31 (1) , 12-22
Open AccessYoung chronic obstructive lung disease or constrictive bronchiolitis: difficulties in differential diagnosis in the context of hostilities
Confirmation of the diagnosis of chronic obstructive pulmonary disease (COPD) in young patients is a difficult but important challenge for respiratory physicians, as it is the key to prescribing the correct therapy and has an important medical and social role. The term “young COPD” is used in the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2026 GOLD Report to refer to patients with COPD aged 20-50 years. The aim of the study was to describe the features of the diagnosis of young COPD and to systematize the latest data on the differential diagnosis with obliterative bronchiolitis. We conducted a literature search on the relevant topics and keywords in the scientific databases PubMed, Google Scholar, Scopus and Web of Science. After a detailed analysis, 53 literature sources were selected and evaluated, 90% of which were published over the past 5 years and contained the most up-to-date information. It has been established that genetic factors prevail over the influence of environmental factors in the development of COPD in young patients, among which the most common cause is congenital alpha-1 antitrypsin deficiency. However, there is a growing trend of airway damage as a result of smoking modern devices for nicotine and tobacco use, such as new generations of e-cigarettes and tobacco heating devices, which are especially popular among youth. The diagnosis of COPD in people younger than 50 years can be considered if the patient has not only persistent post-bronchodilator obstruction, but also presents a long history of smoking (≥10 pack-years) and typical changes on computed tomography of the lungs (emphysema and abnormalities of small or large bronchi). In the context of active hostilities, an important competitive diagnosis in such patients is obliterative bronchiolitis. This disease is manifested by external compression and sometimes obliteration of bronchioles, and should be considered when five factors are combined, including an atypical young age for COPD, typical symptoms, persistent bronchial obstruction on spirometry, the formation of the “air trapping” symptom on computed tomography of the lungs, no signs of emphysema, and an anamnesis of inhalation of toxic substances. Thus, confirmation of the diagnosis of COPD in people under 50 years of age requires a comprehensive assessment of the patient's condition, which should include pulmonary function testing (spirometry), imaging studies (computed tomography of the lungs), and genetic testing (alpha-1 antitrypsin deficiency). Given that in the context of active hostilities related to the War for Independence of Ukraine, both military personnel and civilians may be exposed to significant negative effects of toxic and irritating substances on the respiratory system, obliterative bronchiolitis should be considered as a mandatory component of the differential diagnosis in young patients. To verify the diagnosis of obliterative bronchiolitis, computed tomography of the lungs and confirmation of inhalation of toxic substances are crucial. However, in certain clinical situations, only lung biopsy assessment can distinguish between these two diagnoses.
- Open Access
- 25 March 2026
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 9 (1) , 23-28
Mexidol protection of the glutathione-derived enzyme system of the blood in experimental pulmonary emphysema
BACKGROUND. The paper presents an analysis of literature data on the glutathione-dependent enzyme system, the results of the authors' own studies on disorders in it, and the effect of mexidol in experimental pulmonary emphysema. OBJECTIVE. To study the nature of changes in the glutathione-dependent enzyme system of blood in experimental pulmonary emphysema and the possibility of using mexidol as a protector. MATERIALS AND METHODS. Experimental studies were conducted on 45 sexually mature, outbred white rats weighing 180-200 g. Pulmonary emphysema was reproduced by a single intratracheal injection of 0.5 ml of papain solution at doses of 50 and 100 mg/kg of weight. The activity of glutathione reductase, glutathione-S-transferase and glutathione peroxidase was determined in the blood. To assess the possibility of reactivating enzymes of the glutathione system, mexidol was used, which has a wide spectrum of pharmacological action, based on its antioxidant, antihypoxic, and membrane-protective properties. RESULTS AND DISCUSSION. It was established that the development of pulmonary emphysema is accompanied by impaired function of glutathione reductase, glutathione-S-transferase and glutathione peroxidase. It was shown that these changes are not irreversible. Mexidol promotes reactivation of the glutathione-binding enzyme system. CONCLUSIONS. In experimental pulmonary emphysema, the activity of enzymes of glutathione metabolism is disrupted. The dynamics of changes in the blood indicators of the glutathione enzyme system under the influence of mexidol, its metabolic effect indicate the possibility of using this drug as a protector in pulmonary emphysema.
- 25 March 2026
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 9 (1) , 23-28
Open AccessMexidol protection of the glutathione-derived enzyme system of the blood in experimental pulmonary emphysema
BACKGROUND. The paper presents an analysis of literature data on the glutathione-dependent enzyme system, the results of the authors' own studies on disorders in it, and the effect of mexidol in experimental pulmonary emphysema. OBJECTIVE. To study the nature of changes in the glutathione-dependent enzyme system of blood in experimental pulmonary emphysema and the possibility of using mexidol as a protector. MATERIALS AND METHODS. Experimental studies were conducted on 45 sexually mature, outbred white rats weighing 180-200 g. Pulmonary emphysema was reproduced by a single intratracheal injection of 0.5 ml of papain solution at doses of 50 and 100 mg/kg of weight. The activity of glutathione reductase, glutathione-S-transferase and glutathione peroxidase was determined in the blood. To assess the possibility of reactivating enzymes of the glutathione system, mexidol was used, which has a wide spectrum of pharmacological action, based on its antioxidant, antihypoxic, and membrane-protective properties. RESULTS AND DISCUSSION. It was established that the development of pulmonary emphysema is accompanied by impaired function of glutathione reductase, glutathione-S-transferase and glutathione peroxidase. It was shown that these changes are not irreversible. Mexidol promotes reactivation of the glutathione-binding enzyme system. CONCLUSIONS. In experimental pulmonary emphysema, the activity of enzymes of glutathione metabolism is disrupted. The dynamics of changes in the blood indicators of the glutathione enzyme system under the influence of mexidol, its metabolic effect indicate the possibility of using this drug as a protector in pulmonary emphysema.
- Open Access
- 24 September 2025
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 8 (3) , 12-17
Treatment of severe asthma exacerbations during wartime: analysis of compliance of real practice with the recommendations of clinical guidelines
BACKGROUND. War and martial law conditions create economic, ecological, and psychological prerequisites for worsening the course of bronchial asthma and increasing the risk of its exacerbations. OBJECTIVE. To analyze the compliance of real practice with the recommendations of clinical guidelines in the treatment of severe asthma exacerbations during wartime. MATERIALS AND METHODS. An analysis of 100 medical records of inpatient patients who were treated in healthcare institutions of Ukraine for severe asthma exacerbations in the period from July 2024 to May 2025 was conducted. The drugs intended for the treatment of exacerbations, their pharmacological group, dosage, route of administration and compliance with clinical guidelines were analyzed. RESULTS AND DISCUSSION. The real life practice of treating severe exacerbations of bronchial asthma in martial law generally complies with the recommendations of clinical guidelines, but has certain peculiarities. Controlled oxygen therapy appointment is implemented in medical institutions at an insufficient level (for 2 patients from 100). Complicated severe course of asthma exacerbations sometimes requires systemic corticosteroids therapy in higher doses (125 mg of methylprednisolone in 22 patients) and a longer course (more than 7 days in 81 patients) than recommended. The severity of bronchial obstruction and its causes other than asthma determine the indications for therapy with theophylline and mucolytic (in 34 and 86 patients, respectively), and infectious complications – with antibiotics (in 50 patients). Polymorbidity, especially cardiovascular pathology, determines the need for infusion therapy (in 61 patients). CONCLUSIONS. The course of asthma exacerbations undergoes negative modification during the war and affects the need for their additional treatment.
- 24 September 2025
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 8 (3) , 12-17
Open AccessTreatment of severe asthma exacerbations during wartime: analysis of compliance of real practice with the recommendations of clinical guidelines
BACKGROUND. War and martial law conditions create economic, ecological, and psychological prerequisites for worsening the course of bronchial asthma and increasing the risk of its exacerbations. OBJECTIVE. To analyze the compliance of real practice with the recommendations of clinical guidelines in the treatment of severe asthma exacerbations during wartime. MATERIALS AND METHODS. An analysis of 100 medical records of inpatient patients who were treated in healthcare institutions of Ukraine for severe asthma exacerbations in the period from July 2024 to May 2025 was conducted. The drugs intended for the treatment of exacerbations, their pharmacological group, dosage, route of administration and compliance with clinical guidelines were analyzed. RESULTS AND DISCUSSION. The real life practice of treating severe exacerbations of bronchial asthma in martial law generally complies with the recommendations of clinical guidelines, but has certain peculiarities. Controlled oxygen therapy appointment is implemented in medical institutions at an insufficient level (for 2 patients from 100). Complicated severe course of asthma exacerbations sometimes requires systemic corticosteroids therapy in higher doses (125 mg of methylprednisolone in 22 patients) and a longer course (more than 7 days in 81 patients) than recommended. The severity of bronchial obstruction and its causes other than asthma determine the indications for therapy with theophylline and mucolytic (in 34 and 86 patients, respectively), and infectious complications – with antibiotics (in 50 patients). Polymorbidity, especially cardiovascular pathology, determines the need for infusion therapy (in 61 patients). CONCLUSIONS. The course of asthma exacerbations undergoes negative modification during the war and affects the need for their additional treatment.
- Open Access
- 28 June 2025
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 8 (2) , 5-11
Algorithm for assigning different 6-month short-term chemotherapy regimens in patients with drug-resistant tuberculosis: how to make the right choice for the clinician
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for selecting the optimal 6-month treatment regimen for patients with multidrugresistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) based on an analysis of efficacy, safety, and costeffectiveness. MATERIALS AND METHODS. The study included 337 patients who were prescribed one of four regimens: BPaLM, BPaL, BdqLzdMfxhdCsDlm, or BdqLzdCfz(Mrp)CsDlm. Efficacy, adverse reactions, and treatment costs were evaluated. RESULTS AND DISCUSSION. The highest efficacy (100 %) was demonstrated by the BPaLM regimen. The BPaL regimen was optimal for pre-XDR-TB. The 6-month BdqLzdMfxhdCsDlm and BdqLzdCfz(Mrp)CsDlm regimens are appropriate when Pa-based regimens cannot be used or are limited (e.g., in children under 14 years, pregnant women, in cases of resistance or intolerance to Pa or Lzd). The developed algorithms for assigning various 6-month short-term chemotherapy regimens allow for individualized treatment selection based on Mycobacterium tuberculosis drug susceptibility, comorbidities, potential toxicity, and drug availability, contributing to improved treatment efficacy and reduced failure risk. CONCLUSIONS. The BPaLM regimen is the standard treatment for patients with rifampicin-resistant TB / MDR-TB. For patients with pre-XDR-TB, the BPaL regimen offers the best balance of efficacy, tolerability, and cost-effectiveness. The proposed prescription algorithms enable a personalized treatment approach and improve therapeutic outcomes.
- 28 June 2025
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 8 (2) , 5-11
Open AccessAlgorithm for assigning different 6-month short-term chemotherapy regimens in patients with drug-resistant tuberculosis: how to make the right choice for the clinician
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for selecting the optimal 6-month treatment regimen for patients with multidrugresistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) based on an analysis of efficacy, safety, and costeffectiveness. MATERIALS AND METHODS. The study included 337 patients who were prescribed one of four regimens: BPaLM, BPaL, BdqLzdMfxhdCsDlm, or BdqLzdCfz(Mrp)CsDlm. Efficacy, adverse reactions, and treatment costs were evaluated. RESULTS AND DISCUSSION. The highest efficacy (100 %) was demonstrated by the BPaLM regimen. The BPaL regimen was optimal for pre-XDR-TB. The 6-month BdqLzdMfxhdCsDlm and BdqLzdCfz(Mrp)CsDlm regimens are appropriate when Pa-based regimens cannot be used or are limited (e.g., in children under 14 years, pregnant women, in cases of resistance or intolerance to Pa or Lzd). The developed algorithms for assigning various 6-month short-term chemotherapy regimens allow for individualized treatment selection based on Mycobacterium tuberculosis drug susceptibility, comorbidities, potential toxicity, and drug availability, contributing to improved treatment efficacy and reduced failure risk. CONCLUSIONS. The BPaLM regimen is the standard treatment for patients with rifampicin-resistant TB / MDR-TB. For patients with pre-XDR-TB, the BPaL regimen offers the best balance of efficacy, tolerability, and cost-effectiveness. The proposed prescription algorithms enable a personalized treatment approach and improve therapeutic outcomes.
- Open Access
- 28 June 2025
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 8 (2) , 5-11
Algorithm for assigning different 6-month short-term chemotherapy regimens in patients with drug-resistant tuberculosis: how to make the right choice for the clinician
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for selecting the optimal 6-month treatment regimen for patients with multidrugresistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) based on an analysis of efficacy, safety, and costeffectiveness. MATERIALS AND METHODS. The study included 337 patients who were prescribed one of four regimens: BPaLM, BPaL, BdqLzdMfxhdCsDlm, or BdqLzdCfz(Mrp)CsDlm. Efficacy, adverse reactions, and treatment costs were evaluated. RESULTS AND DISCUSSION. The highest efficacy (100 %) was demonstrated by the BPaLM regimen. The BPaL regimen was optimal for pre-XDR-TB. The 6-month BdqLzdMfxhdCsDlm and BdqLzdCfz(Mrp)CsDlm regimens are appropriate when Pa-based regimens cannot be used or are limited (e.g., in children under 14 years, pregnant women, in cases of resistance or intolerance to Pa or Lzd). The developed algorithms for assigning various 6-month short-term chemotherapy regimens allow for individualized treatment selection based on Mycobacterium tuberculosis drug susceptibility, comorbidities, potential toxicity, and drug availability, contributing to improved treatment efficacy and reduced failure risk. CONCLUSIONS. The BPaLM regimen is the standard treatment for patients with rifampicin-resistant TB / MDR-TB. For patients with pre-XDR-TB, the BPaL regimen offers the best balance of efficacy, tolerability, and cost-effectiveness. The proposed prescription algorithms enable a personalized treatment approach and improve therapeutic outcomes.
- 28 June 2025
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- Vol. 8 (2) , 5-11
Open AccessAlgorithm for assigning different 6-month short-term chemotherapy regimens in patients with drug-resistant tuberculosis: how to make the right choice for the clinician
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for selecting the optimal 6-month treatment regimen for patients with multidrugresistant TB (MDR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) based on an analysis of efficacy, safety, and costeffectiveness. MATERIALS AND METHODS. The study included 337 patients who were prescribed one of four regimens: BPaLM, BPaL, BdqLzdMfxhdCsDlm, or BdqLzdCfz(Mrp)CsDlm. Efficacy, adverse reactions, and treatment costs were evaluated. RESULTS AND DISCUSSION. The highest efficacy (100 %) was demonstrated by the BPaLM regimen. The BPaL regimen was optimal for pre-XDR-TB. The 6-month BdqLzdMfxhdCsDlm and BdqLzdCfz(Mrp)CsDlm regimens are appropriate when Pa-based regimens cannot be used or are limited (e.g., in children under 14 years, pregnant women, in cases of resistance or intolerance to Pa or Lzd). The developed algorithms for assigning various 6-month short-term chemotherapy regimens allow for individualized treatment selection based on Mycobacterium tuberculosis drug susceptibility, comorbidities, potential toxicity, and drug availability, contributing to improved treatment efficacy and reduced failure risk. CONCLUSIONS. The BPaLM regimen is the standard treatment for patients with rifampicin-resistant TB / MDR-TB. For patients with pre-XDR-TB, the BPaL regimen offers the best balance of efficacy, tolerability, and cost-effectiveness. The proposed prescription algorithms enable a personalized treatment approach and improve therapeutic outcomes.
- 20 March 2025
- Published by National Academy of Medical Sciences of Ukraine in JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE
- Vol. 31 (1) , 26
Fundamental studies of cystic fibrosis and the importance of their implementation in clinical practice
Fundamental studies of cystic fibrosis and the importance of their implementation in clinical practice Yuriy I. Feshchenko, Maryna O. Polyanska, Svitlana G. Opimakh State Institution «National Scientific Center of Phthisiatry, Pulmonology and Allergology named after F. G. Yanovsky of the National Academy of Medical Sciences of Ukraine», 10 M. Amosova Str., Kyiv 01038, Ukraine Introduction. Cystic fibrosis (CF) is a genetic (hereditary) disease caused by mutations in the gene encoding the synthesis of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A hundred years ago, most babies with this pathology did not live to 18 months. Today, the average survival age of a child born with CF is about 50 years. The aim: to study the fundamental researches of CF and the significance of their implementation in clinical practice. Materials and methods. A search of sources was conducted in the scientific databases of Elsevier, PubMed® and Google Scholar using the keywords «mucoviscidosis» or «cystic fibrosis» and «study history», «fundamental research», «life expectancy» in Ukrainian and English language publications. 61 literary sources were selected for in-depth analysis. Results. The history of CF is ancient dating back thousands of years. «Cystic fibrosis of the pancreas» was first described as an independent disorder in 1938. The autosomal recessive inheritance pattern for CF was established in 1946. The pilocarpine sweat test was developed in 1959 – a diagnostic test that is still used today. In 1979, thanks to the invention of the serum immunoreactive trypsinogen assay laid the foundation for the development of a population-based early newborn screening program. In 1989, the was made gene was identified, opening new research avenues for both diagnosis and treatment. Since then, it has been possible to establish a diagnosis by direct identification of two mutant alleles of CFTR. A breakthrough in the treatment of CF was made possible by the discovery of CFTR modulators, as they can be used to improve or potentially correct CFTR function and other associated complications. A breakthrough in the treatment of CF was made possible with the discovery of CFTR modulators, as they can be used to improve or potentially correct CFTR function and other associated complications. Conclusions. Cystic fibrosis is an example of a successful interaction between science and practice, when theoretical discoveries have been translated into the clinic with overwhelmingly positive results for patients. It is a rare disease that has become a leader in transformative molecular therapy. The promise of gentic therapy and gene editing approaches to restore CFTR function in the lungs offers unprecedented opportunities to transform CF from a fatal disease to a treatable and potentially curable one. Keywords: cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) gene, sweat test, CFTR modulators, fundamental research.
- 20 March 2025
- Published by National Academy of Medical Sciences of Ukraine in JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE
- Vol. 31 (1) , 26
Fundamental studies of cystic fibrosis and the importance of their implementation in clinical practice
Fundamental studies of cystic fibrosis and the importance of their implementation in clinical practice Yuriy I. Feshchenko, Maryna O. Polyanska, Svitlana G. Opimakh State Institution «National Scientific Center of Phthisiatry, Pulmonology and Allergology named after F. G. Yanovsky of the National Academy of Medical Sciences of Ukraine», 10 M. Amosova Str., Kyiv 01038, Ukraine Introduction. Cystic fibrosis (CF) is a genetic (hereditary) disease caused by mutations in the gene encoding the synthesis of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A hundred years ago, most babies with this pathology did not live to 18 months. Today, the average survival age of a child born with CF is about 50 years. The aim: to study the fundamental researches of CF and the significance of their implementation in clinical practice. Materials and methods. A search of sources was conducted in the scientific databases of Elsevier, PubMed® and Google Scholar using the keywords «mucoviscidosis» or «cystic fibrosis» and «study history», «fundamental research», «life expectancy» in Ukrainian and English language publications. 61 literary sources were selected for in-depth analysis. Results. The history of CF is ancient dating back thousands of years. «Cystic fibrosis of the pancreas» was first described as an independent disorder in 1938. The autosomal recessive inheritance pattern for CF was established in 1946. The pilocarpine sweat test was developed in 1959 – a diagnostic test that is still used today. In 1979, thanks to the invention of the serum immunoreactive trypsinogen assay laid the foundation for the development of a population-based early newborn screening program. In 1989, the was made gene was identified, opening new research avenues for both diagnosis and treatment. Since then, it has been possible to establish a diagnosis by direct identification of two mutant alleles of CFTR. A breakthrough in the treatment of CF was made possible by the discovery of CFTR modulators, as they can be used to improve or potentially correct CFTR function and other associated complications. A breakthrough in the treatment of CF was made possible with the discovery of CFTR modulators, as they can be used to improve or potentially correct CFTR function and other associated complications. Conclusions. Cystic fibrosis is an example of a successful interaction between science and practice, when theoretical discoveries have been translated into the clinic with overwhelmingly positive results for patients. It is a rare disease that has become a leader in transformative molecular therapy. The promise of gentic therapy and gene editing approaches to restore CFTR function in the lungs offers unprecedented opportunities to transform CF from a fatal disease to a treatable and potentially curable one. Keywords: cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) gene, sweat test, CFTR modulators, fundamental research.
- Open Access
- 5 December 2024
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 4,p. 38-43
Screening for and Treatment of Epstein—Barr Virus Infection Reactivation as Rehabilitation Tool in Uncontrolled Asthma Patients Who Have Had COVID-19
Objective — to evaluate the frequency of the reactivation of Epstein—Barr virus (EBV) infection among patients with uncontrolled asthma who have had COVID-19 and to determine its treatment effectiveness as a rehabilitation tool. Materials and methods. The study included 25 uncontrolled asthma patients with post-COVID syndrome. For all patients, we determined the presence of active EBV infection by polymerase chain reaction of saliva and nasopharyngeal samples. For the treatment of uncontrolled asthma patients with post-COVID syndrome and reactivation of EBV infection acyclovir 400 mg 4 times a day for 20 days, proteflazid 15 drops twice daily for 2 months, decametoxin 0.02 % solution nebulizer therapy for 10 days were prescribed. Before and after the therapy, the patients completed the Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ-7). In addition, we performed spirometry and the 6-Minute Walk Test (6MWT) to assess the treatment efficacy. Results and discussion. Reactivation of EBV infection was detected in 19 (76.0 ± 8.5) % of patients with uncontrolled bronchial asthma who have had COVID-19. For these 19 patient we prescribed therapy as listed in materials and methods. Under the treatment, there was a decrease in the severity of respiratory symptoms and an improvement in the control of bronchial asthma symptoms. After two months of treatment, the patients had a statistically significant enhancement in the control of asthma symptoms: ACT increased from (11.8 ± 0.7) to (19.3 ± 0.7) points, ACQ-7 decreased from (2.6 ± 0.1) to (1.1 ± 0.1) points with clinically important and statistical significance (p < 0.05). The pulmonary function, namely the vital and forced vital capacity and the bronchial patency (forced expiratory volume in the first second) improved under the study treatment. The small airways obstruction (mid-expiratory flow) decreased with a statistically significant difference. There was a physical exercise tolerance improvement by the 6MWT. Conclusions. Reactivation of EBV infection is often (76 %) complication of COVID-19. The use of acyclovir, proteflazid and topical decametoxin therapy for these patients allows improving in asthma control according to the ACT and ACQ-7 questionnaires. With the improvement of the pulmonary function test, the exercise tolerance of the patients became better. Screening for and treatment of EBV infection reactivation is a possible rehabilitation element in uncontrolled asthma patients who have had COVID-19.
- 5 December 2024
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 4,p. 38-43
Open AccessScreening for and Treatment of Epstein—Barr Virus Infection Reactivation as Rehabilitation Tool in Uncontrolled Asthma Patients Who Have Had COVID-19
Objective — to evaluate the frequency of the reactivation of Epstein—Barr virus (EBV) infection among patients with uncontrolled asthma who have had COVID-19 and to determine its treatment effectiveness as a rehabilitation tool. Materials and methods. The study included 25 uncontrolled asthma patients with post-COVID syndrome. For all patients, we determined the presence of active EBV infection by polymerase chain reaction of saliva and nasopharyngeal samples. For the treatment of uncontrolled asthma patients with post-COVID syndrome and reactivation of EBV infection acyclovir 400 mg 4 times a day for 20 days, proteflazid 15 drops twice daily for 2 months, decametoxin 0.02 % solution nebulizer therapy for 10 days were prescribed. Before and after the therapy, the patients completed the Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ-7). In addition, we performed spirometry and the 6-Minute Walk Test (6MWT) to assess the treatment efficacy. Results and discussion. Reactivation of EBV infection was detected in 19 (76.0 ± 8.5) % of patients with uncontrolled bronchial asthma who have had COVID-19. For these 19 patient we prescribed therapy as listed in materials and methods. Under the treatment, there was a decrease in the severity of respiratory symptoms and an improvement in the control of bronchial asthma symptoms. After two months of treatment, the patients had a statistically significant enhancement in the control of asthma symptoms: ACT increased from (11.8 ± 0.7) to (19.3 ± 0.7) points, ACQ-7 decreased from (2.6 ± 0.1) to (1.1 ± 0.1) points with clinically important and statistical significance (p < 0.05). The pulmonary function, namely the vital and forced vital capacity and the bronchial patency (forced expiratory volume in the first second) improved under the study treatment. The small airways obstruction (mid-expiratory flow) decreased with a statistically significant difference. There was a physical exercise tolerance improvement by the 6MWT. Conclusions. Reactivation of EBV infection is often (76 %) complication of COVID-19. The use of acyclovir, proteflazid and topical decametoxin therapy for these patients allows improving in asthma control according to the ACT and ACQ-7 questionnaires. With the improvement of the pulmonary function test, the exercise tolerance of the patients became better. Screening for and treatment of EBV infection reactivation is a possible rehabilitation element in uncontrolled asthma patients who have had COVID-19.
- Open Access
- 15 November 2022
- Published by Polonia University in Czestochowa in Scientific Journal of Polonia University
- Vol. 53 (4) , 215-224
PATHOLOGICAL IMMUNITY CHANGES IN COMORBID PATIENTS WITH EXACERBATION OF BRONCHIAL ASTHMA
The aim of the study – to investigate immunological changes in patients with exacerbation of bronchial asthma with different severity and controllability depending on the presence of comorbid pathology. Materials and methods of research. The work is based on the analysis of data from a comprehensive clinical and laboratory examination of 190 patients with exacerbation of asthma. The relative content of T–lymphocytes and their main subpopulations was determined on a flow cytofluorimeter FACS Calibur (Canada) by phenotyping lymphocytes with monoclonal antibodies (BECKMAN COULTER, USA) to surface membrane differentiation antigens (CD): CD3+19– (pan T-cells), CD4+–8+– (T−helpers/inducers), CD4–8+ (cytotoxic T lymphocytes), CD3–16+ (natural killers). To identify the imbalance of immunoregulatory subpopulations of T cells, the immunoregulatory index was calculated – the ratio of the number of CD4+8– Lf and CD4-8+ Lf. To calculate the absolute content in the peripheral blood of individual populations of Lf, leukogram indicators determined on the hematological analyzer ABH-miscros60, France were used. The proliferative activity of lymphocytes was evaluated in cultures of whole blood in the reaction of blast transformation of these cells with morphological accounting of the results. Statistical processing of the obtained data was carried out using licensed software products included in the Microsoft Office Professional 2007 package, license Russian Academic OPEN No Level № 43437596 in Excel. Conclusions. In moderate asthma, the frequency of pathological changes in the T-system of immunity did not depend on the presence of comorbid pathology, as a rule. In severe asthma, an increase in the content of pan–T cells occurred 1.2 times more often than in moderate asthma, but this was not observed in people with concomitant pathology. In this group, the frequency of increasing the content of T–helpers and decreasing the content of cytotoxic T – cells in patients with severe asthma without concomitant diseases was 1.3 times more frequent than in patients with comorbid pathology. No pathological changes in the T–system were detected in patients with controlled asthma. In partially controlled asthma, these changes were registered 1.5 times more often than in controlled asthma, and in its uncontrolled course, the prevalence of pathological changes in the T–system of immunity was much higher than in the two previous groups. In patients with concomitant diseases, these changes, as a rule, had a higher frequency than in patients without comorbid pathology.
- 15 November 2022
- Published by Polonia University in Czestochowa in Scientific Journal of Polonia University
- Vol. 53 (4) , 215-224
Open AccessPATHOLOGICAL IMMUNITY CHANGES IN COMORBID PATIENTS WITH EXACERBATION OF BRONCHIAL ASTHMA
The aim of the study – to investigate immunological changes in patients with exacerbation of bronchial asthma with different severity and controllability depending on the presence of comorbid pathology. Materials and methods of research. The work is based on the analysis of data from a comprehensive clinical and laboratory examination of 190 patients with exacerbation of asthma. The relative content of T–lymphocytes and their main subpopulations was determined on a flow cytofluorimeter FACS Calibur (Canada) by phenotyping lymphocytes with monoclonal antibodies (BECKMAN COULTER, USA) to surface membrane differentiation antigens (CD): CD3+19– (pan T-cells), CD4+–8+– (T−helpers/inducers), CD4–8+ (cytotoxic T lymphocytes), CD3–16+ (natural killers). To identify the imbalance of immunoregulatory subpopulations of T cells, the immunoregulatory index was calculated – the ratio of the number of CD4+8– Lf and CD4-8+ Lf. To calculate the absolute content in the peripheral blood of individual populations of Lf, leukogram indicators determined on the hematological analyzer ABH-miscros60, France were used. The proliferative activity of lymphocytes was evaluated in cultures of whole blood in the reaction of blast transformation of these cells with morphological accounting of the results. Statistical processing of the obtained data was carried out using licensed software products included in the Microsoft Office Professional 2007 package, license Russian Academic OPEN No Level № 43437596 in Excel. Conclusions. In moderate asthma, the frequency of pathological changes in the T-system of immunity did not depend on the presence of comorbid pathology, as a rule. In severe asthma, an increase in the content of pan–T cells occurred 1.2 times more often than in moderate asthma, but this was not observed in people with concomitant pathology. In this group, the frequency of increasing the content of T–helpers and decreasing the content of cytotoxic T – cells in patients with severe asthma without concomitant diseases was 1.3 times more frequent than in patients with comorbid pathology. No pathological changes in the T–system were detected in patients with controlled asthma. In partially controlled asthma, these changes were registered 1.5 times more often than in controlled asthma, and in its uncontrolled course, the prevalence of pathological changes in the T–system of immunity was much higher than in the two previous groups. In patients with concomitant diseases, these changes, as a rule, had a higher frequency than in patients without comorbid pathology.
- Open Access
- 25 May 2022
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 1,p. 7-15
Lung lever after COVID-19: clinical-X-ray, surgical and morphological characteristics
MATERIALS AND METHODS. Preliminary clinical and morphological analysis of a group of patients with various post-COVID complications and with surgical treatment was performed. For the period 2020-2021 in the clinic of thoracic surgery of the SI “National institute of phthisiology and pulmonology named after F.G. Yanovsky of the NAMS of Ukraine” 12 patients were treated who had coronavirus disease (COVID-19) in anamnesis and underwent surgery for COVID-19 complications. RESULTS AND DISCUSSION. Data on the type of surgery, X-ray conclusion and preliminary clinical diagnoses of patients with post-COVID pulmonary complications are presented. At the time of surgical treatment, according to clinical data, 4 (22.2 %) patients were diagnosed with lung abscess, 4 (22.2 %) patients had a disseminated process in the lungs of unclear origin, 2 (11.0 %) – a solitary formation of the lung, one (5.5 %, respectively) observation – spontaneous pneumothorax and suspected tumor of the lung. The results of the histopathological conclusion on the operative material and the final clinical diagnosis in the group of patients with atypical lung lesions after COVID-19 are presented. The results of histopathological examination showed that after 3 months and more after recovery from COVID-19 in some patients there are persistent pathological changes in lung tissue of various characters, and quantitatively among them prevail cases of various pathologies associated with damage to the vascular bed of the lungs. CONCLUSIONS. In most cases of pulmonary complications after suffering COVID-19, preliminary clinical diagnoses did not fully correspond to the identified pathological process. Morphological examination of the operative material of patients with a history of COVID-19 and postcocious complications associated with the lungs, found that vascular pulmonary pathology predominates: persistent microvasculitis of small blood vessels, pulmonary infarction, metacarpal metaplasia, secondary vascular malformation.
- 25 May 2022
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 1,p. 7-15
Open AccessLung lever after COVID-19: clinical-X-ray, surgical and morphological characteristics
MATERIALS AND METHODS. Preliminary clinical and morphological analysis of a group of patients with various post-COVID complications and with surgical treatment was performed. For the period 2020-2021 in the clinic of thoracic surgery of the SI “National institute of phthisiology and pulmonology named after F.G. Yanovsky of the NAMS of Ukraine” 12 patients were treated who had coronavirus disease (COVID-19) in anamnesis and underwent surgery for COVID-19 complications. RESULTS AND DISCUSSION. Data on the type of surgery, X-ray conclusion and preliminary clinical diagnoses of patients with post-COVID pulmonary complications are presented. At the time of surgical treatment, according to clinical data, 4 (22.2 %) patients were diagnosed with lung abscess, 4 (22.2 %) patients had a disseminated process in the lungs of unclear origin, 2 (11.0 %) – a solitary formation of the lung, one (5.5 %, respectively) observation – spontaneous pneumothorax and suspected tumor of the lung. The results of the histopathological conclusion on the operative material and the final clinical diagnosis in the group of patients with atypical lung lesions after COVID-19 are presented. The results of histopathological examination showed that after 3 months and more after recovery from COVID-19 in some patients there are persistent pathological changes in lung tissue of various characters, and quantitatively among them prevail cases of various pathologies associated with damage to the vascular bed of the lungs. CONCLUSIONS. In most cases of pulmonary complications after suffering COVID-19, preliminary clinical diagnoses did not fully correspond to the identified pathological process. Morphological examination of the operative material of patients with a history of COVID-19 and postcocious complications associated with the lungs, found that vascular pulmonary pathology predominates: persistent microvasculitis of small blood vessels, pulmonary infarction, metacarpal metaplasia, secondary vascular malformation.